Abstract

A fit-for-purpose structural and statistical model is the first major requirement in population pharmacometric model development. In this manuscript we discuss how this complex and computationally intensive task could benefit from supervised machine learning algorithms. We compared the classical pharmacometric approach with two machine learning methods, genetic algorithm and neural networks, in different scenarios based on simulated pharmacokinetic data. Genetic algorithm performance was assessed using a fitness function based on log-likelihood, whilst neural networks were trained using mean square error or binary cross-entropy loss. Machine learning provided a selection based only on statistical rules and achieved accurate selection. The minimization process of genetic algorithm was successful at allowing the algorithm to select plausible models. Neural network classification tasks achieved the most accurate results. Neural network regression tasks were less precise than neural network classification and genetic algorithm methods. The computational gain obtained by using machine learning was substantial, especially in the case of neural networks. We demonstrated that machine learning methods can greatly increase the efficiency of pharmacokinetic population model selection in case of large datasets or complex models requiring long run-times. Our results suggest that machine learning approaches can achieve a first fast selection of models which can be followed by more conventional pharmacometric approaches.

Highlights

  • Model-informed drug discovery and development (MID3) is a process which applies quantitative modeling to preclinical and clinical data to accelerate and optimize drug development [1]

  • We demonstrated that machine learning methods can greatly increase the efficiency of pharmacokinetic population model selection in case of large datasets or complex models requiring long run-times

  • Our results suggest that machine learning approaches can achieve a first fast selection of models which can be followed by more conventional pharmacometric approaches

Read more

Summary

Introduction

Model-informed drug discovery and development (MID3) is a process which applies quantitative modeling to preclinical and clinical data to accelerate and optimize drug development [1]. Among the techniques available in MID3, population modeling is a tool which describes the relationships between patientsphysiological characteristics and model parameters governing drug concentrations, or drug response and their distribution across a population [6]. Population pharmacokinetic (PK) and PD models are used to describe relationships between a dependent variable (e.g., concentration or response) and an independent variable (e.g., time). These models are used to investigate sources of variability [7]. Population models favor statistical (nonlinear) mixed effect modeling techniques.

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call